MILAN, Italy, May 11 /PRNewswire/ -- Eurand, a specialty pharmaceutical company, announced today that a US pharmaceutical partner had recently submitted a New Drug Application (NDA) to the US Food and Drug Administration. The subject of this submission is a customized release formulation of an undisclosed compound which was developed by Eurand and utilizes its Diffucaps(R) technology. Eurand will exclusively manufacture the product which will be sold in the US by its partner.
Gearoid Faherty, Chief Executive Officer of Eurand, commented, “This is the third NDA to be filed with the FDA using our proprietary Diffucaps technology in the last four years and this is a testament to the applicability of the technology. We look forward to the approval of the product by the FDA and a successful commercial launch.”
About Eurand
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The Company specializes in bioavailability enhancement of poorly soluble drugs, modified release and taste masking and is currently developing a pipeline of products based on its proprietary Biorise(R) technology. Eurand also works with many of the world’s leading pharmaceutical and biotechnology companies to develop enhanced forms of their existing products and development compounds. Eurand’s principal operating offices are in Milan, Italy while Eurand’s US business is directed from Eurand, Inc. in Vandalia, Ohio. The Company has research, development and manufacturing facilities in Italy and the United States and manufacturing facilities in France.
Eurand
CONTACT: Gearoid Faherty, CEO of Eurand, (Italy) +39-02-954281,bizdev@eurand.com
Web site: http://www.eurand.com/
